HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD By Yuan Yuan, MD, PhD There have been so many exciting things in our field, most recently including antibody drug conjugates specifically Trastuzumab Deruxtecan a monoclonal antibody in the HER2 low disease had largely changed our … Continue reading HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD